NDAORALSOLUTION
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZIRA is a fixed-dose oral solution combining hydrocodone bitartrate (opioid analgesic) and pseudoephedrine hydrochloride (nasal decongestant). It is indicated for relief of cough and nasal congestion associated with upper respiratory conditions. The opioid component suppresses cough reflex while the decongestant reduces sinus/nasal swelling.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%), suggesting stable but not expanding commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on REZIRA offers experience in mature brand management, opioid compliance/REMS navigation, and competitive strategy in a crowded cough-cold segment. Career growth is limited by product maturity; roles are focused on market defense and operational efficiency rather than innovation.
Brand ManagerField Sales Representative
Worked on REZIRA at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.